What Biolabo does

Biolabo S.A.S., founded in 1979 in Maizy, France, develops, manufactures, and markets in vitro diagnostic reagents, automated analyzers, and antibodies for medical biology laboratories worldwide. It is the reagents-producing entity within the privately held BIOLABO GROUP, alongside BPC BioSed S.R.L. (Italy, analyzer manufacturer since 1986, acquired 2016) and ABLIANCE (France, antibody manufacturer since 1981). The product portfolio spans biochemistry and TIA reagents (both dedicated barcode-coded formats for proprietary analyzers and polyvalent formats open to other platforms), lyophilized coagulation reagents for the SOLEA range, calibrators and controls, slide tests, and a full analyzer line that includes the KENZA biochemistry range (KENZA MAX, KENZA MAX PLUS, KENZA ONE at 100 tests/hour, KENZA 240 TX, and KENZA 450 TX at 420 tests/hour) and the SOLEA coagulation range (SOLEA QUICK, BIO SOLEA 2, BIO SOLEA 4, SOLEA 100). Reagents and analyzers are paired through barcode-based, pre-validated, pre-programmed containers and connect bidirectionally to Laboratory Information Systems.

Biolabo operates almost entirely through B2B channels. The dominant model is an exclusive distributor network with one certified partner per country, supported by engineers and technicians trained in France; approximately 97% of production is exported through this channel into more than 80 countries and over 100 active distributors. A secondary OEM channel white-labels analyzers under partner brands for specific geographies or commercial sectors subject to minimum quantities, while a smaller direct channel sells to healthcare professionals in metropolitan France. Reported differentiators include up to 36-month reagent shelf life, full ISO 9001:2015 and ISO 13485:2016 certification, CE marking under IVD Directive 98/79/EC, integrated barcode/LIS workflows, and a 40-year track record with more than 10,000 analyzers installed globally.

Beyond the core medical biology laboratory segment (cardiovascular, diabetes, hepatitis, obesity, routine clinical chemistry, coagulation studies), Biolabo targets veterinary laboratories, the agrofood industry, oenology/viticulture, and pharmaceutical quality control. The pricing model is unit-based B2B with free metropolitan France shipping above EUR 300 ex-tax, EUR 49 processing fees below, and 30-day payment terms. No public financial data, venture funding, or stock-market listing is disclosed; the company remains a private subsidiary of BIOLABO GROUP, a diversified industrial group.

Name

Biolabo

Legal name

BIOLABO S.A.S.

Website

https://biolabo.fr

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

11–50 employees

Short description

Biolabo S.A.S., founded in 1979 in Maizy, France, develops, manufactures, and markets in vitro diagnostic reagents, automated analyzers, and antibodies for medical biology laboratories worldwide, distributed through exclusive certified partners in more than 80 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Maizy

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Reagent Sales: Sale of biochemistry reagents, TIA reagents, coagulation reagents, calibrators, controls, and slide tests for medical biology diagnostics. Reagents are recognized for their long shelf life (up to 36 months), stability, linearity, and reliability.
2. Analyzer Sales: Sale of automated biochemistry analyzers (KENZA and GLOBAL ranges) and coagulation analyzers (SOLEA range). Analyzers marketed by BPC BioSed.
3. OEM Partnerships: For certain geographic areas or activity sectors, analyzers are marketed as OEM under partner brands. Subject to specific markets and minimum quantities.
4. Antibody Sales (via ABLIANCE): Antibodies manufactured and marketed by ABLIANCE, part of BIOLABO GROUP, for medical diagnostics applications.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

BIOLABO develops, manufactures, and markets in vitro diagnostic (IVD) medical devices for medical biology laboratories, including biochemistry reagents, coagulation reagents, calibrators and controls, slide tests, and a portfolio of automated analyzers under the KENZA, SOLEA, and GLOBAL brands (marketed by group company BPC BioSed). The group also produces monoclonal and polyclonal antibodies via ABLIANCE. Integrated reagent-analyzer solutions are offered with pre-programmed, barcoded dedicated reagents.

Product overview

BIOLABO is an in vitro diagnostic company offering a comprehensive portfolio of reagents and analysers for medical biology. The product portfolio consists of two main categories: (1) Reagents including Biochemistry & TIA reagents (available as dedicated barcode-coded formats for KENZA/GLOBAL analysers or polyvalent formats for manual/semi-automated techniques), Coagulation reagents for the SOLEA range, Calibrators & Controls, and Slide Tests; and (2) Analysers marketed under two sub-brands: BIOLABO's KENZA range (biochemistry: KENZA MAX, KENZA MAX PLUS, KENZA ONE, KENZA 240 TX, KENZA 450 TX; coagulation: SOLEA QUICK, BIO SOLEA 2, BIO SOLEA 4, SOLEA 100) and BPC BioSed's GLOBAL range (GLOBAL 240, GLOBAL 4500DR, each available with optional ISE modules). BIOLABO GROUP controls both reagent and analyser production since acquiring BPC BioSed in 2016, offering integrated analyser + dedicated reagent solutions.

Differentiator

Problem solved

Functional benefit

Brands

• BPC BioSed: Brand for biochemistry and coagulation analysers marketed by BPC BioSed S.R.L.
• ABLIANCE
• KENZA
• SOLEA
• GLOBAL
• OEM

Products and services

• KENZA MAX BioChemisTry

Quantifiable outcome

• Up to 36-month shelf life for reagents
• +4 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature6 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Regione LaziominorOthers · 1 January 2010Partnership with Regione Lazio for supporting training and employment initiatives in the Italian region, including job posting for biomedical support engineer positions.
• BPC BioSed S.R.L.coreChannel Partner/ Reseller/ DistributorBPC BioSed S.R.L., based in Castelnuovo di Porto, Rome, Italy, is the exclusive marketer of all BIOLABO GROUP analyzers. Founded in 1986, BPC BioSed develops, produces, and distributes automatic analyzers. Acquired by BIOLABO GROUP in 2016, it now operates as part of the group with combined reagent and analyzer manufacturing capabilities.
• ABLIANCEcoreChannel Partner/ Reseller/ DistributorABLIANCE, founded in 1981 (originally as BIOSYS, then P.A.R.I.S., and ABLIANCE since 2015), is part of BIOLABO GROUP and specializes in antibody manufacturing. It was among the first companies to produce monoclonal antibodies in hollow fiber cytocultors. ABLIANCE markets all antibodies for BIOLABO GROUP.
• OEM Brand PartnersminorOEM/ Whitelabel/ Licensing PartnerFor certain geographic areas or activity sectors, BIOLABO GROUP analyzers are marketed as OEM under partner brands. Several brands already trust BIOLABO GROUP for OEM partnerships. OEM production is subject to specific markets or commercial fields and minimum quantities.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Mindray: Large Chinese IVD manufacturer with broad clinical chemistry, hematology, and coagulation analyzer lines plus reagent menus; competes with BIOLABO in the same lab segments but at significantly larger scale and with deeper direct-sales reach in emerging markets.
• bioMérieux: France-headquartered global IVD major with biochemistry (once including the discontinued BioMérieux chemistry line), microbiology, and immunoassay offerings; sets the competitive ceiling for French IVD players like BIOLABO and exerts pricing pressure across distributor channels.

Emerging players

• Agappe Diagnostics: India-based IVD company focused on clinical chemistry reagents and benchtop/semi-automated analyzers; an emerging mid-tier player targeting similar distributor-driven expansion into emerging markets where BIOLABO is also present.

Direct peers

• ELITech Group: France-headquartered IVD company with a comparable mid-tier positioning, offering clinical chemistry reagents, coagulation analyzers, and dedicated analyzer-reagent systems distributed globally through country-level distributors — directly analogous to BIOLABO's model.
• Spinreact (part of Werfen): Spanish IVD reagent manufacturer with biochemistry, coagulation, and urinalysis reagents plus dedicated analyzer lines, distributed internationally — a near-direct functional equivalent of BIOLABO's reagent + analyzer model.
• Cypress Diagnostics: Belgium-based IVD manufacturer of clinical chemistry reagents and semi-automated/automated analyzers, distributed globally with a strong emerging-market footprint similar to BIOLABO's 80+ country reach.
• Horiba Medical: Japan-based IVD player producing clinical chemistry, hematology, and coagulation analyzers with global distribution; comparable in offering integrated reagent-analyzer solutions for mid-sized hospital and reference labs.
• Erba Mannheim: European (Germany) IVD manufacturer with a similar mid-tier product portfolio spanning clinical chemistry reagents, hematology, and semi-automated to fully-automated analyzers, distributed internationally through distributor networks in emerging and developed markets.
• Audit Diagnostics: Ireland-based IVD manufacturer producing clinical chemistry reagents, controls, and dedicated analyzer systems with distributor-led international sales — a similar-sized European competitor with overlapping product lines.
• Randox Laboratories: UK-based IVD manufacturer offering a broad portfolio of clinical chemistry reagents, controls/calibrators, and dedicated RX-series analyzers with global distribution — closely mirrors BIOLABO's integrated reagent-analyzer approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks3 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biolabo

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biolabo